As tar­get­ed ther­a­pies get ever more pre­cise, Deer­field un­veils $50M bet on a Har­vard pro­fes­sor's chem­istry in­sights

Be­hind the seem­ing­ly sim­ple con­cept of tar­get­ed can­cer ther­a­pies is the drug de­vel­op­er’s headache that the tar­get is al­ways chang­ing. Each gen­er­a­tion of ki­nase in­hibitors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER